
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
Case: A 59-Year Old Female With Stage IIIC Ovarian Cancer
Initial Presentation
Clinical work-up
Treatment
Follow-up






